BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 24515340)

  • 1. Structural modification of an EGFR inhibitor that showed weak off-target activity against RET leading to the discovery of a potent RET inhibitor.
    Sun QZ; Xu Y; Liu JJ; Zhang CH; Wang ZR; Zheng RL; Wang WJ; Li LL; Yang SY
    Mol Divers; 2014 May; 18(2):403-9. PubMed ID: 24515340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and optimization of selective RET inhibitors via scaffold hopping.
    Luo Z; Wang L; Fu Z; Shuai B; Luo M; Hu G; Chen J; Sun J; Wang J; Li J; Chen S; Zhang Y
    Bioorg Med Chem Lett; 2021 Sep; 47():128149. PubMed ID: 34058344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
    Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
    Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.
    Yoon H; Shin I; Nam Y; Kim ND; Lee KB; Sim T
    Eur J Med Chem; 2017 Jan; 125():1145-1155. PubMed ID: 27814560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.
    Li Y; Tan C; Gao C; Zhang C; Luan X; Chen X; Liu H; Chen Y; Jiang Y
    Bioorg Med Chem; 2011 Aug; 19(15):4529-35. PubMed ID: 21724404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold.
    Brandt W; Mologni L; Preu L; Lemcke T; Gambacorti-Passerini C; Kunick C
    Eur J Med Chem; 2010 Jul; 45(7):2919-27. PubMed ID: 20409618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET kinase inhibitors.
    Graham Robinett R; Freemerman AJ; Skinner MA; Shewchuk L; Lackey K
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5886-93. PubMed ID: 17884497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and RET protein kinase inhibitory activity of 3-arylureidobenzylidene-indolin-2-ones.
    Rizzi E; Cassinelli G; Dallavalle S; Lanzi C; Cincinelli R; Nannei R; Cuccuru G; Zunino F
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3962-8. PubMed ID: 17499504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
    La Pietra V; Sartini S; Botta L; Antonelli A; Ferrari SM; Fallahi P; Moriconi A; Coviello V; Quattrini L; Ke YY; Hsing-Pang H; Da Settimo F; Novellino E; La Motta C; Marinelli L
    Eur J Med Chem; 2018 Apr; 150():491-505. PubMed ID: 29549836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.
    Frett B; Moccia M; Carlomagno F; Santoro M; Li HY
    Eur J Med Chem; 2014 Oct; 86():714-23. PubMed ID: 25232968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
    Meng S; Wu H; Wang J; Qiu Q
    Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.
    Li X; Su J; Yang Y; Lian W; Deng Z; Yang Z; Chen G; Zhang B; Dong C; Liu X; Li L; Wang Z; Hu Z; Xu Q; Deng X
    Eur J Med Chem; 2020 Dec; 207():112755. PubMed ID: 32882611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 4-chloro-3-(5-(pyridin-3-yl)-1,2,4-oxadiazole-3-yl)benzamides as novel RET kinase inhibitors.
    Han M; Li S; Ai J; Sheng R; Hu Y; Hu Y; Geng M
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5679-5684. PubMed ID: 27815117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationship study of pyrazolo[3,4-d]pyrimidines as tyrosine kinase RET inhibitors.
    Wang C; Liu H; Song Z; Ji Y; Xing L; Peng X; Wang X; Ai J; Geng M; Zhang A
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2544-2548. PubMed ID: 28404375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
    Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anilinoquinazoline inhibitors of the RET kinase domain-Elaboration of the 7-position.
    Jordan AM; Begum H; Fairweather E; Fritzl S; Goldberg K; Hopkins GV; Hamilton NM; Lyons AJ; March HN; Newton R; Small HF; Vishwanath S; Waddell ID; Waszkowycz B; Watson AJ; Ogilvie DJ
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2724-9. PubMed ID: 27086121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of
    Mologni L; Dalla Via M; Chilin A; Palumbo M; Marzaro G
    ChemMedChem; 2017 Aug; 12(16):1390-1398. PubMed ID: 28639308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.
    Akeno-Stuart N; Croyle M; Knauf JA; Malaguarnera R; Vitagliano D; Santoro M; Stephan C; Grosios K; Wartmann M; Cozens R; Caravatti G; Fabbro D; Lane HA; Fagin JA
    Cancer Res; 2007 Jul; 67(14):6956-64. PubMed ID: 17638907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.
    Yang J; Wang LJ; Liu JJ; Zhong L; Zheng RL; Xu Y; Ji P; Zhang CH; Wang WJ; Lin XD; Li LL; Wei YQ; Yang SY
    J Med Chem; 2012 Dec; 55(23):10685-99. PubMed ID: 23116168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor.
    Bugge S; Kaspersen SJ; Larsen S; Nonstad U; Bjørkøy G; Sundby E; Hoff BH
    Eur J Med Chem; 2014 Mar; 75():354-74. PubMed ID: 24556149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.